论文部分内容阅读
CHMP建议批准礼来(Lilly)公司、Amylin公司和Alkermes公司合作开发的艾塞那肽缓释注射混悬剂(商品名为Bydureon,产品规格为2 mg,每周给药1次)在欧盟上市,用于那些使用最大口服剂量降糖药仍无法控制血糖的2型糖尿病患者。若获得
CHMP recommends approval of exenatide sustained release injection suspension (Bydureon, product spec. 2 mg, once a week) developed by Lilly, Amylin and Alkermes in the European Union For patients with type 2 diabetes who are unable to control their blood sugar using the largest oral dose of hypoglycemic agents. If you get it